Are lower MRPs on cancer drugs translating into affordable care?
- The National Pharmaceutical Pricing Authority (NPPA) imposed price caps on several high-cost oncology medicines in 2022.
- Since the caps, the Maximum Retail Prices (MRPs) of flagship cancer drugs such as imatinib and trastuzumab fell by 15-30 percent.
- Despite lower MRPs, out-of-pocket spending on cancer treatment remains above 25% of average household income due to ancillary costs like diagnostics and hospital charges.
- Only about 12% of diagnosed cancer patients in India currently have access to fully affordable treatment under existing price‑control mechanisms.
- Increased generic entry after patent expiries is gradually improving drug availability, but supply chain bottlenecks limit the impact.
